QIAGEN’s Eco-Friendlier Products Earn Prestigious ACT Label
May 19 2022 - 4:05PM
Business Wire
- QIAwave products showed 35% lower environmental
impact
- First in industry to receive ACT label for sample
preparation kits
- QIAGEN and My Green Lab to collaborate on laboratory
sustainability efforts
QIAGEN N.V. (NYSE: QGEN; Frankfurt Prime Standard: QIA) today
announced that its recently launched, environmentally friendlier
QIAwave nucleic-acid extraction kits have received the prestigious
ACT Environmental Impact Factor Label from My Green Lab, a
non-profit organization dedicated to advancing sustainability in
scientific research.
In awarding the ACT (Accountability, Consistency, and
Transparency) labels, My Green Lab found that the three QIAwave
products had a 35% improved Environmental Impact Factor when
compared to QIAGEN’s standard kits, taking into account such
criteria as, manufacturing impact reduction, responsible chemical
management, product and packaging content as well as disposal of
packaging.
QIAGEN launched the QIAwave portfolio in January with the
QIAwave RNA Mini Kit, QIAwave DNA Blood & Tissue Kit and
QIAwave Plasmid Miniprep Kit. All are designed to use fewer
components and produce less waste, and are the first such kits to
use both recycled plastics and space-saving chemical concentrates.
They represent the first wave of QIAGEN’s sustainability-driven
product innovations and a major step in reducing the environmental
impact of the company’s overall portfolio.
To date, My Green Lab has awarded the ACT label to more than
4,000 products across the global life sciences industry, with
QIAGEN’s products the first nucleic-acid extraction kits to receive
this stamp of approval from the respected independent arbiter.
Going forward, QIAGEN will closely collaborate with the
California-based organization to advance its Green Lab
Certification Program, which aims to increase transparency around
the environmental impact of research laboratories, and work toward
certification of QIAGEN’s own research and development labs.
"My Green Lab puts the spotlight on companies to meet head-on
the immense ecological challenges facing planet Earth," said Thomas
Schweins, Senior Vice President and Head of QIAGEN’s Life Science
Business Area. "We at QIAGEN take that challenge very seriously.
Today’s recognition of our eco-friendlier kits is another
proof-point of our commitment to sustainability and an important
milestone in our campaign to significantly reduce the environmental
impact of our entire product range."
QIAGEN aims to reduce plastic packaging waste by a further 9% in
2022, following a 9.6% reduction achieved in 2021. The company’s
Plastic Footprint Task Force, founded in 2018, manages initiatives
such as replacing expanded-polystyrene boxes for cooled shipments
with recyclable alternatives. Beyond reducing its plastic
footprint, QIAGEN has pledged to cut carbon emissions in line with
the goal of reaching the Science Based Targets Net-Zero Standard by
2050, and constantly monitors its global environmental impact,
economic influence and corporate citizenship. The sustainability
agency ISS ESG has given QIAGEN its highest “Prime” rating.
More information about QIAwave ACT labels can be found here.
More information about QIAGEN’s vision of a sustainable future
can be found here.
About QIAGEN QIAGEN N.V., a Netherlands-based holding
company, is the leading global provider of Sample to Insight
solutions that enable customers to gain valuable molecular insights
from samples containing the building blocks of life. Our sample
technologies isolate and process DNA, RNA and proteins from blood,
tissue and other materials. Assay technologies make these
biomolecules visible and ready for analysis. Bioinformatics
software and knowledge bases interpret data to report relevant,
actionable insights. Automation solutions tie these together in
seamless and cost-effective workflows. QIAGEN provides solutions to
more than 500,000 customers around the world in Molecular
Diagnostics (human healthcare), Applied Testing (primarily
forensics), Pharma (pharma and biotech companies) and Academia
(life sciences research). As of March 31, 2022, QIAGEN employed
more than 6,000 people in over 35 locations worldwide. Further
information can be found at http://www.qiagen.com.
Forward-Looking Statement Certain statements contained in
this press release may be considered forward-looking statements
within the meaning of Section 27A of the U.S. Securities Act of
1933, as amended, and Section 21E of the U.S. Securities Exchange
Act of 1934, as amended. To the extent that any of the statements
contained herein relating to QIAGEN's products, collaborations
markets, strategy or operating results, including without
limitation its expected adjusted net sales and adjusted diluted
earnings results, are forward-looking, such statements are based on
current expectations and assumptions that involve a number of
uncertainties and risks. Such uncertainties and risks include, but
are not limited to, risks associated with management of growth and
international operations (including the effects of currency
fluctuations, regulatory processes and dependence on logistics),
variability of operating results and allocations between customer
classes, the commercial development of markets for our products to
customers in academia, pharma, applied testing and molecular
diagnostics; changing relationships with customers, suppliers and
strategic partners; competition; rapid or unexpected changes in
technologies; fluctuations in demand for QIAGEN's products
(including fluctuations due to general economic conditions, the
level and timing of customers' funding, budgets and other factors);
our ability to obtain regulatory approval of our products;
difficulties in successfully adapting QIAGEN's products to
integrated solutions and producing such products; the ability of
QIAGEN to identify and develop new products and to differentiate
and protect our products from competitors' products; market
acceptance of QIAGEN's new products and the integration of acquired
technologies and businesses. For further information, please refer
to the discussions in reports that QIAGEN has filed with, or
furnished to, the U.S. Securities and Exchange Commission
(SEC).
Source: QIAGEN N.V. Category: Corporate
View source
version on businesswire.com: https://www.businesswire.com/news/home/20220519005947/en/
QIAGEN: Investor Relations John Gilardi, +49 2103 29
11711 Phoebe Loh, +49 2103 29 11457 ir@QIAGEN.com
Public Relations Thomas Theuringer, +49 2103 29 11826
pr@QIAGEN.com
Qiagen NV (NYSE:QGEN)
Historical Stock Chart
From Aug 2024 to Sep 2024
Qiagen NV (NYSE:QGEN)
Historical Stock Chart
From Sep 2023 to Sep 2024